Solute carrier proteins and the uptake of cytotoxic approved drugs

Informazioni relative al progetto

DrugsUP

ID dell’accordo di sovvenzione: 661491

DOI

10.3030/661491

Progetto chiuso

Data della firma CE 28 Aprile 2015

Data di avvio 1 Maggio 2015

Data di completamento 30 Aprile 2017

Finanziato da

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Costo totale

€ 178 156,80

Contributo UE

€ 178 156,80

Coordinato da

CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
Austria

Periodic Reporting for period 1 - DrugsUP (Solute carrier proteins and the uptake of cytotoxic approved drugs)

Periodo di rendicontazione: 2015-05-01 al 2017-04-30

Sintesi del contesto e degli obiettivi generali del progetto

The transport of nutrients and metabolites across lipid membranes is a critical and essential biological process in both normal and pathological conditions. Specialized integral membrane proteins known as transporters are responsible for the movement of virtually any known class of biologically active molecules across membranes. Perhaps not surprisingly, there is increasing evidence that many drugs in clinical use also use carried-mediated transport as the predominant entry method into the cell. Understanding the molecular and physiological basis of transporter-mediated drug uptake is therefore a key step toward the development of improved pharmacokinetics and models of toxicity for current and future therapeutically active compounds. We hypothesized that most approved drugs may require specific members of the solute carrier (SLC) family to cross the cell membrane, a phenomenon that would directly affect the compound activity, and that this process is basically underestimated in its importance. To test this hypothesis, the studies performed aimed at identifying SLC transporters involved in the uptake of a well-characterized set of commercialized drugs by a functional genetics screening approach. By screening a large panel of drugs in the HAP1 human cell line with a focused, custom-made CRISPR/Cas9 library, we identify a large number of SLC-drug associations that encompass both known and novel interactions.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Within the project we generated a set of tools to study systematically the largely uncharacterized family of solute carrier (SLCs), comprising most of the human membrane transporters. In particular, we generated a library of CRISPR/Cas9 constructs able to selectively inactivate SLCs genes in human cells, allowing us to screen for genes that are involved in determining the potency of cytotoxic approved drugs (such as for example antitumour drugs). A large set of such compounds (>50) was identified and tested with the library, yielding a number of SLC-drug associations that are now undergoing validation to confirm and understand further their role and mechanism of action. By using different concentration of the compounds, we were able to find correlation between the strength of the hit SLCs and the selective pressure applied, providing an additional layer of validation. Importantly, we identify many known SLC-drug associations (such for example the role of folate transporters in anti-folate drugs uptake or the role of nucleoside transporters in decitabine/cytarabine uptake) therefore confirming the robustness of our approach. The results generated will be disseminated by both presentation at international conferences and by scientific publications, currently in preparation.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

The identification of a set of novel drug interactions is an exciting progress in a highly understudied field with the potential to improve the distribution and potency of drugs and improve our understanding of side effects and interaction with other compounds. By knowing how drugs enter cells and how metabolism influences the potency of a drug, it would be possibly to design compounds with improved efficacy (improved metabolism, increased uptake), a better distribution profile (higher uptake, less excretion) and limited side effects (by for example targeting only specific organs based on the pattern of transporters expressed). As these are some of the factors that critically affect the rate at which new compounds are approved for clinical use, we expect that these findings will have large and significant societal and economic implications.

drugsup-graphicalsummary.png